Stereotactic radiotherapy and thoracic tumor radiotherapy group

Zhuang Hongqing, deputy chief physician, is the group leader of stereotactic radiotherapy and thoracic tumor radiotherapy.

Dr. Zhuang Hongqing is also a member of the lung cancer group of the Chinese Medical Association Radiotherapy Branch; Member of the lung cancer group of the China Anti-Cancer Association Radiotherapy Branch; Standing member of the Thoracic Oncology Professional Committee of the Interventional Society of China Anti-Cancer Association; standing member of the Radiation Therapy Branch of the China Medical Education Association; Standing member of the Radiation Therapy Committee of the Beijing Medical Association; Standing member of the lung cancer professional committee of Beijing Cancer Research Association; Deputy Head of the Central Oncology Group of the Radiation Therapy Branch of the Beijing Medical Association; Standing member of the lung cancer professional committee of Beijing Oncology Society; Standing member of the Immunotherapy Professional Committee of Beijing Cancer Research Association; Member of the Radiation Therapy Branch of Beijing Medical Awards Foundation.

Dr. Zhuang is particularly good at two cutting-edge areas of tumor radiotherapy: stereotactic radiotherapy, radiotherapy combined targeting and immunotherapy. He is a famous practical doctor of stereotactic radiotherapy in China. Zhuang Hongqing started to work in the treatment of radiographic knife in 2007. He is one of the earliest clinical stereotactic experts in China who has been engaged in stereotactic radiotherapy. In 2017, he started to work in Peking University Third Hospital.

The Cyberknife is a whole-body stereotactic radiosurgery treatment equipment, also known as " robotic stereotactic radiosurgery ". The Cyberknife is the latest equipment of the cross era development of computer technology and industrial manufacturing technology. It is the most cutting-edge radiosurgery technology in recent years. It has the characteristics of small side effects, high treatment accuracy and short treatment time (3-5 days). Cyberknife has excellent effect on intracranial metastasis and primary tumor, lung cancer and pulmonary metastasis, liver cancer and liver metastasis, pancreatic cancer, adrenal metastasis, pelvic tumor, spine primary and metastatic tumor, bone and soft tissue tumor, etc. In 2016, the Peking University Third Hospital introduced the Iris Cyberknife, which is the most advanced in China. It is handier for the treatment of complex lesions, can kill tumors to a greater extent without dead angle, and create a new era of stereotactic radiotherapy. At present, the patients in the Third Hospital of Beijing Medical College are at the leading level in China and have rich experience in stereotactic radiotherapy.

The thoracic tumor group was mainly for lung cancer, esophageal cancer, thymoma and other diseases. After years of development, the thoracic tumor group has experienced a lot of doctors and therapists, who are able to implement accurate radiotherapy positioning (4D-CT), respiratory gated radiotherapy, image-guided radiotherapy, stereotactic radiotherapy and other radiotherapy technologies. At the same time, Dr. Zhuang Hongqing, as the first doctor engaged in radiotherapy combined with targeting and immunotherapy in China, has a profound understanding and very experienced in radiotherapy combined with targeting and immunotherapy of thoracic tumors.